2-Propanol: Clinical Trials

4 trials of 2-Propanol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 withdrawn. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 2, Recruiting 1, Withdrawn 1
Phase 21Recruiting 1

Follow 2-Propanol: new trials by email Literature Review of 2-Propanol trials Research Report on 2-Propanol

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Propranolol Treatment for Postoperative Chylothorax
Propranolol Hydrochloride, Placebo - Postoperative Chylothorax, Congenital Heart Disease
Phase 1 / Phase 2RecruitingJune Wu502025-09-092026-11-18
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Cobimetinib, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1CompletedCity of Hope Medical Center32023-04-282026-05-05
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia
Phase 1WithdrawnCity of Hope Medical Center2022-06-252022-06-09
Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA
Chloraprep, 0.9% Physiological Saline, ZuraPrep without IPA - Surgical Site Infection
Phase 1CompletedZurex Pharma, Inc.2082014-07-012015-03-17

Conditions studied

Leukemia, Myeloid, Acute (2)  ·  Chylothorax (1)  ·  Heart Defects, Congenital (1)  ·  Surgical Wound Infection (1)

Sponsors

City of Hope Medical Center (2)  ·  June Wu (1)  ·  Zurex Pharma, Inc. (1)

Countries

United States (4)

Top investigators

Brian Ball (1)  ·  Guido Marcucci (1)  ·  June Wu, MD (1)  ·  Maggie Butler, PhD (1)

NIH funding

P30CA033572 (2)